Pedro Barata, MD, MSc, FACP, University Hospitals Seidman Cancer Center, and Christopher Wallis, MD, PhD, FRCSC, University of Toronto, continue their discussion, pivoting to a discussion on the efficacy of pembrolizumab/lenvatinib and how this IO/TKI approach compares to other frontline treatment strategies for advanced RCC.
Comparing Combination Treatment Approaches in Front-Line Advanced RCC
By Pedro Barata, MD, Christopher Wallis, MD, PhD, FRCSC - Last Updated: May 1, 2024Related Posts
Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.
Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.
The combination therapy provided similar survival rates and toxicity in an older patient population.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
First-line IO + IO therapy is linked to higher costs during the first three months of treatment.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.